A carregar...

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

BACKGROUND: Despite recent advances in treating non‐small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK‐positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK‐positive NSCLC. METHODS: Between 2011 and 2018, a total of 14 A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Heo, Ja Yoon, Park, Changhee, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Miso, Kim, Tae Min, Kim, Dong‐Wan, Kim, Se Hyun, Kim, Yu Jung, Lee, Jong Seok, Heo, Dae Seog
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825904/
https://ncbi.nlm.nih.gov/pubmed/31509890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13195
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!